Pharmaceuticals, Biotechnology and Life Sciences
After nearly five years of follow-up, median progression-free survival was not reached, and a significant overall survival benefit was observed;…
New subcutaneous, fixed-dose formulation of daratumumab reduces treatment time from hours to minutes, with comparable efficacy and fewer infusion-related reactions1,2…
BEERSE, Belgium–(BUSINESS WIRE)–The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human…
The addition of daratumumab – or in this particular study – Darzalex to bortezomib, lenalidomide and dexamethasone (VRd) induced higher response rates in newly diagnosed patients with multiple myeloma who were eligible for high-dose therapy and autologous stem cell transplantation (ASCT) compared with VRd alone.
Data supporting the application demonstrated that the investigational subcutaneous formulation improved quality of life, reduced administration time, lowered rates of…
First DARZALEX combination regimen being pursued as frontline treatment option for transplant eligible patients with multiple myeloma BEERSE, Belgium–(BUSINESS WIRE)–The…
Application supported by the Phase 3 MAIA study for daratumumab in combination with lenalidomide and dexamethasone for the treatment of…
BMS and Janssen Biotech announced continuation of their work together through a new clinical research.
The U.S. Food and Drug Administration (FDA) has approved Darzalex (daratumumab) injection for intravenous infusion for the treatment of patients with multiple myeloma